Advertisement

Topics

Aerpio starts dosing in Phase IIb trial of diabetic retinopathy drug

19:00 EDT 2 Jul 2017 | Net Resources International

US-based Aerpio Pharmaceuticals has started dosing patients in the Phase IIb (TIME-2b) clinical trial of its product candidate AKB-9778, which could be used to treat patients with non-proliferative diabetic retinopathy.

Original Article: Aerpio starts dosing in Phase IIb trial of diabetic retinopathy drug

NEXT ARTICLE

More From BioPortfolio on "Aerpio starts dosing in Phase IIb trial of diabetic retinopathy drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...